Abstract 194P
Background
γδ T cells are a small subset (0.5-5%) of peripheral blood T cells playing a key role in both defense against a wide range of pathogens and anticancer immunity. In recent years, Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the treatment of B-cell malignancies. Although primarily expressed in B-cell lineage cells, BTK expression has also been identified in other cell types. However, the role of BTK expression and the impact of BTK inhibitors on non-B cells, including γδ T cells, remain unclear.
Methods
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats using density gradient centrifugation. Selective γδ T cell expansion was achieved by adding zoledronic acid and IL-2. On day 14 of culturing, ibrutinib, acalabrutinib, or zanubrutinib were introduced. After 48 hours of co-incubation, cytokine production and γδ T cell activation were assessed. To evaluate the impact of BTK inhibitors on γδ T cell activation, HMBPP or the CLL cell line Duller was used as stimulation agents. Cytokine production was evaluated by stimulating the cells with M. tuberculosis lysate, PHA, HMBPP, or anti-CD3 [OKT3], followed by cell permeabilization, staining with specific antibodies, and analysis using flow cytometry.
Results
Ibrutinib significantly reduced the production of IFN-γ and TNF-α by γδ T cells stimulated with HMBPP, but not with Duller cells. This suggests that TCR-independent stimulation pathways, such as through the NK family of receptors, may restore cytokine production to normal levels. No significant differences were found in the production of granzyme B, IL-6, IL-9, IL-10, or IL-17a. All inhibitors reduced the early activation of γδ T cells, as indicated by decreased CD69 expression, while having no effect on late-stage activation. Interestingly, this inhibitory effect was least pronounced with ibrutinib.
Conclusions
BTK inhibitors seem to modulate γδ T cell function, with their impact being pathway-specific and potentially partially reversible depending on the type of stimulation. Moreover, newer inhibitors appear to have a lesser impact on γδ T cells, likely due to their higher specificity for BTK. From an immunotherapeutic perspective, concomitant treatment with BTK inhibitors and in vitro expanded γδ T cells could be a viable option.
Legal entity responsible for the study
Medical University of Lublin.
Funding
DKMS Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract